Related Experiment Video
Updated: May 29, 2026
06:43
Robotic Duodenal Sleeve Resection for Gastrointestinal Stromal Tumor with Rare Exon 8 KIT Mutation Following Neoadjuvant Imatinib
Published on: April 3, 2026
Gastrointestinal stromal tumor surgery and adjuvant therapy
Valerie P Grignol1, Paula M Termuhlen
1Department of Surgery, Wright State University Boonshoft School of Medicine, Miami Valley Hospital, One Wyoming Street, WCHE 7000, Dayton, OH 45409, USA.
The Surgical Clinics of North America
|September 6, 2011
Summary
Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors. Targeted tyrosine kinase inhibitors offer effective treatment, necessitating updated management recommendations.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- Gastrointestinal stromal tumors (GIST) are a distinct category of mesenchymal neoplasms.
- Recent advancements in molecular and genetic research have significantly improved understanding of GIST.
- Surgical resection is the primary treatment, but targeted therapies are emerging.
Purpose of the Study:
- To characterize GIST through molecular and genetic studies.
- To develop effective treatment strategies for GIST.
- To provide updated clinical recommendations for GIST management.
Main Methods:
- Intensive molecular and genetic analysis of GIST.
- Review of current treatment modalities, including surgery and targeted therapy.
- Convening a task force for guideline development.
Main Results:
- Tyrosine kinase inhibitor therapy has shown significant efficacy in GIST treatment.
- The rapid accumulation of knowledge necessitates continuous updates in GIST management.
- National Comprehensive Cancer Network (NCCN) convened a GIST task force in 2010.
Conclusions:
- GIST management is evolving rapidly due to ongoing research.
- Regular updates to treatment recommendations are crucial for optimal patient care.
- Targeted therapies represent a paradigm shift in GIST treatment.
